Role of 131 I in the treatment of well differentiated thyroid cancer
dc.contributor.author | Woodrum, Derek T. | en_US |
dc.contributor.author | Gauger, Paul G. | en_US |
dc.date.accessioned | 2006-04-19T13:38:27Z | |
dc.date.available | 2006-04-19T13:38:27Z | |
dc.date.issued | 2005-03-01 | en_US |
dc.identifier.citation | Woodrum, Derek T.; Gauger, Paul G. (2005)."Role of 131 I in the treatment of well differentiated thyroid cancer." Journal of Surgical Oncology 89(3): 114-121. <http://hdl.handle.net/2027.42/34527> | en_US |
dc.identifier.issn | 0022-4790 | en_US |
dc.identifier.issn | 1096-9098 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/34527 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=15719384&dopt=citation | en_US |
dc.description.abstract | 131 I is an integral component in postsurgical management of well-differentiated thyroid cancer (WDTC), which includes papillary and follicular types. 131 I is used postsurgically to either destroy remaining thyroid tissue (thyroid ablation) or to treat recurrence and metastases (radioiodine therapy). 131 I is no longer a routine diagnostic modality, but it is widely used for remnant ablation after thyroidectomy for WDTC > 1 cm, under conditions of thyroxine withdrawal. It is generally—though not unanimously—accepted that postsurgical radioiodine is the most powerful method by which to lengthen disease-free survival. 131 I cannot be used if the residual thyroid remnant is large; many surgeons therefore perform near-total or total thyroidectomy for all WDTC > 1 cm. Since 1997, radioiodine treatment has been performed in outpatient settings, where side effects are common, but mild and transient. Secondary screening is by physical exam, thyroglobulin measurements, and 131 I diagnostic whole-body scans. This is performed under conditions of thyrotropin stimulation, which is accomplished either by thyroxine withdrawal or administration of recombinant human thyrotropin. While most cancers are well treated with radioiodine, some advanced cancers may no longer take up radioiodine, rendering them resistant to treatment. For these cancers, redifferentiation therapy and molecular target-specific medicines hold future promise for improved treatment. J. Surg. Oncol. 2005;89:114–121. © 2005 Wiley-Liss, Inc. | en_US |
dc.format.extent | 98047 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.subject.other | Cancer Research, Oncology and Pathology | en_US |
dc.title | Role of 131 I in the treatment of well differentiated thyroid cancer | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbsecondlevel | Surgery and Anesthesiology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Division of Endocrine Surgery, University of Michigan Department of Surgery, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | Division of Endocrine Surgery, University of Michigan Department of Surgery, Ann Arbor, Michigan ; Assistant Professor of Surgery and Medical Education, Division of Endocrine Surgery, University of Michigan Department of Surgery, 1500 East Medical Center Drive, Taubman Center TC2920H, Ann Arbor, MI 48109-0331. Fax: 734-936-5830. | en_US |
dc.identifier.pmid | 15719384 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/34527/1/20185_ftp.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1002/jso.20185 | en_US |
dc.identifier.source | Journal of Surgical Oncology | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.